Impact of incomplete surgery and adjuvant chemotherapy for the intraoperative rupture of capsulated stage I epithelial ovarian cancer: a multi-institutional study with an in-depth subgroup analysis

被引:7
|
作者
Yoshihara, Masato [1 ]
Tamauchi, Satoshi [1 ]
Iyoshi, Shohei [1 ,2 ]
Kitami, Kazuhisa [1 ]
Uno, Kaname [1 ,3 ]
Mogi, Kazumasa [1 ]
Kajiyama, Hiroaki [1 ]
机构
[1] Nagoya Univ, Dept Obstet & Gynecol, Grad Sch Med, Nagoya, Aichi, Japan
[2] Univ Freiburg, Inst Surg Pathol, Fac Med, Freiburg, Germany
[3] Lund Univ, Dept Lab Med, Fac Med, Lund, Sweden
关键词
Adjuvant Chemotherapy; Fertility Effect; Lymph Node Excision; Ovarian Cancer; Rupture; Spontaneous; FALLOPIAN-TUBE; SURVIVAL; CARCINOMA;
D O I
10.3802/jgo.2021.32.e66
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of the present study was to examine the effects of incomplete surgery and adjuvant chemotherapy on the prognosis of patients with intraoperative rupture of capsulated stage I epithelial ovarian cancer (OvCa). Methods: A regional retrospective study was conducted between 1986 and 2019. Among 4,730 patients with malignant ovarian tumors, 534 women with International Federation of Gynecology and Obstetrics stage IA and IC1 epithelial OvCa were eligible. Differences in survival outcomes were examined between patients with stage IA and IC1 tumors and the effects of uterine preservation, complete-staging lymphadenectomy, and adjuvant chemotherapy were investigated by an in-depth subgroup analysis. To analyze therapeutic effects, baseline imbalances were adjusted using propensity score (PS). Results: The prognosis of patients with stage IC1 tumors was worse than those with stage IA. Surgical spill did not affect the site of recurrence. In the PS-adjusted subgroup analysis, uterine preservation (hazard ratio [HR]=1.669; 95% confidence interval [CI]=1.052-2.744), incomplete-staging lymphadenectomy (HR=1.689; 95% CI=1.211-2.355), and the omission of adjuvant chemotherapy (HR=3.729; 95% Cl=2.090-6.653) significantly increased the HR of recurrence for patients with stage IC1 tumors compared to those with stage IA tumors. Adjuvant chemotherapy decreased the impact of rupture with uterine preservation (HR=0.159; 95% CI=0.230-1.168) or incomplete-staging lymphadenectomy (HR=0.987; 95% CI=0.638-1.527). Conclusion: The present results suggest intraoperative rupture of capsulated stage I epithelial OvCa is associated with a poor prognosis. When chemotherapy is given for patients receiving incomplete surgery, there is no longer an increased risk of recurrence observed with the rupture.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database
    Nasioudis, Dimitrios
    Mastroyannis, Spyridon A.
    Ko, Emily M.
    Haggerty, Ashley F.
    Cory, Lori
    Giuntoli II, Robert L.
    Kim, Sarah H.
    Morgan, Mark A.
    Latif, Nawar A.
    GYNECOLOGIC ONCOLOGY, 2022, 166 (02) : 263 - 268
  • [32] Time-Dependent Trends in Lymph Node Yield and Impact on Adjuvant Therapy Decisions in Colon Cancer Surgery: An International Multi-Institutional Study
    Stojadinovic, Alexander
    Nissan, Aviram
    Wainberg, Zev
    Shen, Perry
    McCarter, Martin
    Protic, Mladjan
    Howard, Robin S.
    Steele, Scott R.
    Peoples, George E.
    Bilchik, Anton
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (13) : 4178 - 4185
  • [33] Time-Dependent Trends in Lymph Node Yield and Impact on Adjuvant Therapy Decisions in Colon Cancer Surgery: An International Multi-Institutional Study
    Alexander Stojadinovic
    Aviram Nissan
    Zev Wainberg
    Perry Shen
    Martin McCarter
    Mladjan Protic
    Robin S. Howard
    Scott R. Steele
    George E. Peoples
    Anton Bilchik
    Annals of Surgical Oncology, 2012, 19 : 4178 - 4185
  • [34] Does complete-staging lymphadenectomy improve survival outcomes in stage I endometrioid epithelial ovarian carcinoma? A multi-institutional retrospective study with propensity score-weighted analysis
    Yoshihara, Masato
    Tamauchi, Satoshi
    Iyoshi, Shohei
    Kitami, Kazuhisa
    Uno, Kaname
    Tano, Sho
    Matsui, Shigeyuki
    Kajiyama, Hiroaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 387 - 392
  • [35] Treatment Outcomes Between Concurrent Chemoradiotherapy and Combination of Surgery, Radiotherapy, and/or Chemotherapy in Stage III and IV Maxillary Sinus Cancer: Multi-Institutional Retrospective Analysis
    Kang, Jung Hun
    Cho, Su Hee
    Kim, Jin Pyeong
    Kang, Ki Mun
    Cho, Kyu Sup
    Kim, Wontaek
    Seol, Young Mi
    Lee, Suee
    Park, Heon Soo
    Hur, Won Joo
    Choi, Young-Jin
    Oh, Sung Yong
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2012, 70 (07) : 1717 - 1723
  • [36] Impact of Intra-peritoneal Chemotherapy and Bevacizumab in Front Line Chemotherapy for Ovarian Cancer Among gBRCA and wtBRCA Patients: A Multi-Institutional, Frequency Matched, Case Control Study
    Liu, A.
    Rowland, M.
    Vesely, S.
    Powell, B.
    Freeman, J.
    Blank, S.
    Frey, M.
    Gillen, J.
    Moore, K.
    Cass, I.
    GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 211 - 211
  • [37] Locoregional recurrence after neoadjuvant versus adjuvant chemotherapy based on tumor subtypes in patients with early-stage breast cancer: A multi-institutional retrospective cohort study
    Cheun, Jong-Ho
    Kwak, Youngji
    Kang, Eunhye
    Jung, Ji-Jung
    Kim, Hong-Kyu
    Lee, Han-Byoel
    Lee, Kyung-Hun
    Moon, Hyeong-Gon
    Hwang, Ki-Tae
    Park, Yeon Hee
    Lee, Jeong Eon
    Han, Wonshik
    BREAST, 2024, 78
  • [38] Taxane-based versus platinum-based chemotherapy in early recurrent gastric cancer after radical surgery with S-1 adjuvant chemotherapy: A multi-institutional retrospective analysis
    Nagaoka, Sakae
    Yamashita, Hiroharu
    Seto, Yasuyuki
    Fujisaki, Muneharu
    Mitsumori, Norio
    Oshima, Yoko
    Yajima, Satoshi
    Kikuchi, Yoshinori
    Otsuka, Koji
    Murakami, Masahiko
    Fujita, Shohei
    Futawatari, Nobue
    Shimada, Hideaki
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (06) : 540 - 545
  • [39] Surgical Efforts Might Mitigate Difference in Response to Neoadjuvant Chemotherapy in Stage IIIC-IV Unresectable Ovarian Cancer: A Case-Control Multi-institutional Study
    Raspagliesi, Francesco
    Bogani, Giorgio
    Matteucci, Laura
    Casarin, Jvan
    Sabatucci, Ilaria
    Tamberi, Stefano
    Arcangeli, Valentina
    Maltese, Giuseppa
    Lepori, Stefano
    Comerci, Giuseppe
    Stefanetti, Marco
    Ditto, Antonino
    Martinelli, Fabio
    Chiappa, Valentina
    Lorusso, Domenica
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (09) : 1706 - 1713
  • [40] Is adjuvant chemotherapy necessary for young women with early-stage epithelial ovarian cancer who have undergone fertility-sparing surgery?: a multicenter retrospective analysis
    Yoshiki Ikeda
    Masato Yoshihara
    Nobuhisa Yoshikawa
    Akira Yokoi
    Satoshi Tamauchi
    Kimihiro Nishino
    Kaoru Niimi
    Hiroaki Kajiyama
    BMC Women's Health, 22